These findings support a model in which T cell activation can be initiated and/or perpetuated locally in sural nerve biopsies of patients with CIDP and vasculitic neuropathy and predict an important role for Schwann cells and endothelial cells.
Introduction
Chronic inflammatory demyelinating polyneuropathy (CIDP) and vasculitic neuropathy are peripheral nerve disorders of presumed autoimmune etiology. A role for T lymphocytes has been suggested based on the observation that T cell infiltrates are present in biopsy specimens and postmortem material of peripheral nerves 1;25-28 . Further support for T cell involvement in the pathogenesis of CIDP comes from the notion that these patients have increased frequencies of circulating activated and chronically stimulated peripheral T lymphocytes and elevated levels of soluble interleukin-2 receptors 4;5 .
Although T lymphocytes are accepted to play a role in the development and/or perpetuation of the inflammatory disease process, little is known about the processes and (auto)antigen(s) responsible for the initiation and chronic course of these neuropathies 29;30 . Generally, T cell activation and migration into peripheral tissues is a selective, multi-step process involving a myriad of molecules expressed or induced on different cell types. The initial events leading to T cell activation are: 1) adhesion and extravasation, 2) recognition of previously captured and processed antigen, presented on MHC class I or II by a professional antigen presenting cell (APC) and 3) recognition of costimulatory molecules like the classic examples CD80 (B7.1) and CD86 (B7.2) on the APC.
Subsequently the T cell will proliferate and differentiate into an effector cell. Normally these events take place in the lymphnodes, but in autoimmune disease the immune response directed to specific autoantigens may be initiated locally. Unlike in Guillain-Barré syndrome (GBS), in CIDP or vasulitic neuropathy a link between preceding infections with micro-organisms and the occurrence of disease has not been established. Thus, although a role for exogenous antigens cannot be excluded, the initial immune response may also be induced by and directed against a nerve-specific or vascular autoantigen. In that case the presence of molecules for adhesion, antigen presentation and costimulation in peripheral nerve tissue is a prerequisite.
The anatomical site(s), cells and molecules that contribute to the autoimmune response resulting in the development of CIDP or vasculitic neuropathy have not been well-established. Here, we have performed an immunohistochemical analysis of cells and molecules involved in adhesion,
antigen presentation and T cell costimulation in sural nerve biopsies of patients with CIDP, vasculitic neuropathy and, as a control, individuals without peripheral neuropathy. The results support the concept that in the sural nerve microenviroment in CIDP and especially vasculitic patients, presentation of autoantigen and local T cell stimulation may contribute to the initiation and/or perpetuation of disease.
Materials and Methods

Patients
Nerve biopsies from 7 patients with CIDP and 3 patients with vasculitic polyneuropathy without evidence for systemic vasculitis were included in the present study. The characteristics of the patients and nerve biopsies are listed in Table 1 . The CIDP biopsies widely varied in the number of infiltrating T cells as we reported recently 28 . Patients 1-3 had increased numbers of T cells compared with normal controls 28 . Patient 2 had received treatment with intravenous immunoglobulin 2 months before the biopsy was taken. As normal controls, biopsy specimens were obtained from individuals that did not suffer from polyneuropathies and succumbed from subarachnoidal bleeding or pulmonary embolism.
Immunohistochemical techniques
Serial transverse tissue sections of 6 µm were made on a cryostat and fixed in acetone. For staining with the S100 antibody, acetone treatment was preceded by fixation with 4%
paraformaldehyde. The staining procedure for all antibodies (Table 2 ) was as follows: biopsies were incubated overnight with the primary antibody diluted in PBS/1% BSA, supplemented with 5% horse or goat serum. Biopsies were rinsed with PBS and incubated for one hour with the biotinylated secondary antibody (rabbit IgG/IgM or mouse IgG; Vector, Peterborough, England) diluted 1:200 in PBS/1% BSA, followed by an one hour incubation with ABC peroxidase (Vector). Color was developed with Nickel and Cobalt enhanced diaminobenzidine. The sections were counterstained with Nuclear fast red, which also stains the myelin sheaths, before dehydration and mounting. Black and white microphotographs were taken without filter resulting in a grey counterstaining and a black diaminobenzidine staining in the pictures.
Optimal dilution for primary antibodies were first determined using tissue sections of human tonsil and skin. These tissues also served as positive controls during each round of staining. In negative control stainings, the same procedure was followed except that the primary antibody was omitted.
In a first round of staining, sets of three serial sections were cut and the middle section was stained with the CD3 monoclonal antibody to confirm the presence of infiltrating T lymphocytes.
The first and third section were used for staining with monoclonal antibodies specific for 
Results
Immunohistochemical procedures and dilutions of antibodies were validated by staining tissue sections of human skin and tonsil. Using the dilutions listed in Table 2 , all antibodies showed specific staining with anticipated distribution patterns of positive cells in human skin sections (anti CD1a) or human tonsil sections (all other antibodies) [31] [32] [33] . No detectable background staining was observed using these conditions. Staining of skin sections with the CD1a-specific monoclonal antibody showed the presence of CD1a+ Langerhans cells. In tonsil sections, CD40 positive clusters of B lymphocytes, CD80 and CD1d positive germinal center B cells, and CD86, CD83, and CD1b positive interdigitating reticulum dendritic cells were clearly identified (not shown). Pat CD54 CD58 HLA-DR CD1a CD1b CD1c CD1d CD40 CD80 CD83 CD86 (Fig. 1a) . In the sural nerve biopsies of all normal controls and patients with polyneuropathy analyzed, CD54 expression was found on the endothelial cells lining endoneurial vessels, whereas no staining of epineurial arterioles was observed (Fig. 1b) . No other cell types in the biopsy specimens expressed the CD54 molecule.
The adhesion molecule CD58 (lymphocyte function-associated molecule 3, LFA-3), is known to be expressed on the surface of epithelial and endothelial cells and erythrocytes. We observed expression of CD58 by myelinating (Nuclear fast red-positive) and non-myelinating (Nuclear fast red-negative) Schwann cells in sural nerve biopsies of all 3 vasculitic neuropathy patients and 5
CIDP patients (Fig. 2a) . In all 3 vasculitic neuropathy patients but only in 1 out of 5 CIDP patients, CD58 was also present on endothelial cells in both the epineurium and endoneurium (Fig. 2e) . In contrast, no CD58 staining was observed in the sural nerve biopsies of normal controls (Fig. 2d) .
Staining with an antibody specific for CD68, a widely used marker for cells of the macrophage/monocyte lineage and of dendritic cells, unveiled the presence of CD68+ cells in the endoneurium and epineurium. The CD68+ cells did not co-localise with the CD58+ Schwann cells (Fig. 2b) . CD1a (not shown) and strongly expressed CD1b (Fig 4a) . In two vasculitic neuropathy patients and 4 CIDP patients, CD1c expression was observed in cells with a perivascular localization (Fig   4b) . Staining of serial sections with a CD20 antibody confirmed that these CD1c+ cells belong to the B lymphocyte lineage (Fig. 4c ) No CD1d expression was detected (not shown).
Finally, CD83 expression was not detectable in any of the nerve biopsy specimens studied. (Fig. 5a) , whereas a complete absence of staining was observed with two IgG monoclonal antibodies specific for CD80 (Innogenetics, Ghent, Belgium), even in T cell rich areas ( Fig. 5b and 5c) . It was recently shown that the BB1 monoclonal antibody recognizes both CD80 and the cell surface form of the invariant chain (CD74) 37 . We conclude that the Schwann cells do not express CD80 yet express high levels of CD74, a molecule that associates with MHC class II molecules to prevent peptide binding. We Weakly CD86-positive endothelial cells were detected in 2 vasculitic neuropathy patients but not in the other biopsy specimens, despite the presence of CD3+ T lymphocytes (Fig. 6a-c ).
Figure 5
Nerve biopsy section of CIDP patient C5 stained with the Pharmingen anti CD80 antibody (a). Serial sections of the nerve biopsy of patient C3 demonstrate the presence of T cells using anti CD3 antibodies (Fig 6b) and the absence of CD80 using the anti CD80 (Innogenetics, 5B5) monoclonal antibodies. Bars: 50µm.
Discussion
We have studied the expression of adhesion-, antigen presenting-, and costimulatory molecules by cells present in peripheral nerves of normal controls and patients with CIDP and vasculitic polyneuropathy. These molecules are involved in homing, priming and expansion of T lymphocytes and the analysis of their expression patterns in normal and disease-associated peripheral nerve tissue may contribute to the understanding of the pathogenesis of inflammatory peripheral neuropathies. Although in our study only the sural nerve was investigated and the disease process may well involve various other and more proximal nerves, the sural nerves in all vasculitic neuropathy patients and 3 of the 7 CIDP patients showed increased numbers of T cells compared with normal and non-inflammatory disease controls as was measured in a previous study 28 .
One of the most salient findings of the current study is that the CD58 (LFA-3) molecule was found on myelinating and non-myelinating Schwann cells in sural nerve biopsies of all 3 vasculitic neuropathy patients and 5 CIDP patients. In striking contrast, no CD58 staining was observed in the sural nerve biopsies of normal controls. The CD58 molecule, a member of the Ig superfamily, is expressed on both hematopoietic and non-hematopoietic cell types. CD58
functions as an adhesion molecule and mediates signal transduction through its counter-receptor CD2 expressed on natural killer cells and T lymphocytes. Signaling via CD58/CD2 induces IL-12 responsiveness of activated T cells during their maturation into effector cells, resulting in T cell proliferation, development of cytotoxic potential and production of -IFN 38 . In model systems, it has been shown that increased levels of CD58 expression correlates with increased production of the cytokines -IFN, IL2 and TNF by effector T lymphocytes and may increase susceptibility The results of the present study support a model in which T cell activation can be initiated and/or perpetuated locally in sural nerve biopsies of patients with CIDP and vasculitic neuropathy and predict an important role for Schwann cells and endothelial cells.
